Therapie chronischer Schmerzen mit oralem retardiertem Oxycodon: Behandlungsdaten von 4196 Patienten

Publikation: Beitrag in FachzeitschriftForschungsartikelBeigetragenBegutachtung

Beitragende

  • J. Gaertner - , Universität zu Köln (Autor:in)
  • M. Frank - , Mundipharma Research GmbH Limburg (Autor:in)
  • B. Bosse - , Mundipharma Research GmbH Limburg (Autor:in)
  • R. Sabatowski - , Universitätsklinikum Köln (Autor:in)
  • F. Eisner - , RWTH Aachen University (Autor:in)
  • T. Giesecke - , Universität zu Köln (Autor:in)
  • L. Radbruch - , RWTH Aachen University (Autor:in)

Abstract

Oral controlled-release oxycodone has been available for the treatment of chronic pain in Germany since 1998. Controlled trials have shown good clinical efficacy and tolerability. This survey reports results from six open prospective multicenter trials. In these trials 4196 patients suffering from cancer pain and non-cancer-related pain with inadequate pain relief were treated with oral controlled-release oxycodone for 3-4 weeks. Only a few participating physicians were pain specialists. A total of 356 patients suffering from pain of the musculoskeletal system and receiving oxycodone therapy were monitored for 6 months. Exclusion from the studies was due mainly to inadequate analgesia, side effects, and non-compliance. The efficacy of oxycodone was rated to be better than moderate by most of the patients, quality of life parameters increased significantly, and patient satisfaction was high. The treatment with oral controlled-release oxycodone was a safe and effective option even when used by non-specialized physicians.

Details

OriginalspracheDeutsch
Seiten (von - bis)61-68
Seitenumfang8
FachzeitschriftSchmerz
Jahrgang20
Ausgabenummer1
PublikationsstatusVeröffentlicht - Feb. 2006
Peer-Review-StatusJa
Extern publiziertJa

Externe IDs

PubMed 15926076

Schlagworte

Ziele für nachhaltige Entwicklung

Schlagwörter

  • Cancer pain and non-cancer-related pain, Efficacy, Opioid therapy, Oxycodone, Safety